Secondary outcome | Measure |
---|---|
Drug-specific outcomes | The absolute number of PIPs per patient of the top five occurring PIP drugs: [11] |
Proton pump inhibitor (PPI) for peptic ulcer disease at full therapeutic dosage for >8Â weeks | |
Long-term (>3Â months) use of NSAIDs for relief of mild joint pain in osteoarthritis | |
Long-term (>1Â month) use of long-acting benzodiazepines, for example, chlordiazepoxide, flurazepam, nitrazepam, chlorazepate and benzodiazepines with long-acting metabolites for example, diazepam | |
Any regular duplicate drug class prescription | |
TCAs with an opiate or calcium channel blocker | |
Mean number of PIPs per patient of the top five PIP drugs (as above) | |
Patient-reported outcomes | Health status (EQ-5D) |
Patients’ Beliefs about Medicine Questionnaire (BMQ) | |
Well-being Questionnaire (WBQ-12) | |
Process-of-care measures | Number of GP visits (6Â months prior to enrolment and at 4 and 12Â month follow-up) |
Number of hospital admissions (6Â months prior to enrolment and at 4 and 12Â month follow-up | |
Process evaluations | Decisions made per PIP |
Number of times alternatives were prescribed | |
Reported primary reason for decision made for example, risks outweigh benefits, patient preference, hospital/consultant initiated |